Skip to main content
SINOTHERAPEUTICS INC. logo

SINOTHERAPEUTICS INC. — Investor Relations & Filings

Ticker · 688247 ISIN · CNE100005PL9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2025-04-29 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688247

About SINOTHERAPEUTICS INC.

https://www.sinotph.com/en/

Sinotherapeutics Inc. is a pharmaceutical company specializing in the research, development, and commercialization of complex generic drugs and innovative drug delivery systems. The company focuses on high-barrier formulations, particularly oral solid dosage forms with modified-release or controlled-release profiles. Utilizing advanced technology platforms, Sinotherapeutics develops products designed to improve patient compliance and therapeutic outcomes. Its operations encompass the full lifecycle of drug development, from formulation design and clinical evaluation to large-scale manufacturing under global quality standards. The company maintains a robust pipeline targeting various therapeutic areas, including cardiovascular diseases, central nervous system disorders, and metabolic conditions. Sinotherapeutics aims to provide high-quality, affordable medications by leveraging its expertise in complex chemistry and pharmaceutical engineering.

Recent filings

Filing Released Lang Actions
2024年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year 2024 by Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2024, including financial and non-financial internal control defects, audit opinions, and corrective actions. The content is focused on internal control evaluation rather than full financial statements or annual performance. The document length is 4056 characters, which is relatively short but contains detailed internal control evaluation information rather than just an announcement. This type of report is typically classified as an Audit Report / Information (AR) because it deals with internal control evaluation and audit opinions on internal controls, not a full Annual Report (10-K) or Interim Report (IR). It is not a Regulatory Filing (RNS) because it contains substantive evaluation content, not just a certification or announcement. Therefore, the best fit is AR (Audit Report / Information).
2025-04-29 Chinese
第二届监事会第十一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It details the approval of various reports and proposals including the 2024 Annual Report, 2024 Annual Audit Report, 2025 Q1 Report, and other financial and governance matters. However, the document itself does not contain the full reports but references that the full reports are disclosed on the Shanghai Stock Exchange website. The document is relatively short (2174 characters) and serves as an official announcement of the Supervisory Board's meeting resolutions rather than the reports themselves. According to the 'Menu vs Meal' rule, this is an announcement of reports and resolutions, not the reports themselves. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories and is not the full report.
2025-04-29 Chinese
2024年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制审计报告" which translates to "Internal Control Audit Report." It is issued by a certified public accounting firm and addresses the effectiveness of internal controls over financial reporting for the fiscal year ending December 31, 2024. The content includes auditor responsibilities, management responsibilities, and an audit opinion on internal control effectiveness. The document is a standalone audit report focused on internal control over financial reporting, not a full annual report or financial statement. The length is 4129 characters, which is consistent with a detailed audit report but not a brief announcement. Therefore, this document fits the category of Audit Report / Information (AR).
2025-04-29 Chinese
2024年度环境、社会和公司治理报告
Environmental & Social Information Classification · 95% confidence The document is titled "2024 年度环境、社会和公司治理报告" which translates to "2024 Environmental, Social and Governance (ESG) Report." It covers detailed disclosures on economic, environmental, social, and governance responsibilities and performance for the year 2024. The content includes company overview, product innovation, social responsibility initiatives, governance practices, and key performance indicators related to ESG. It references standards such as the UN SDGs, GRI Standards, and other social responsibility guidelines. The document is comprehensive and contains substantive data and analysis on ESG factors rather than just an announcement or summary. Therefore, it fits the category of Environmental & Social Information (ESG) report.
2025-04-29 Chinese
对外担保管理制度（2025年4月）
Governance Information Classification · 95% confidence The document is a detailed internal policy document titled '上海宣泰医药科技股份有限公司 对外担保管理制度' which translates to 'Shanghai Xuantai Pharmaceutical Technology Co., Ltd. External Guarantee Management System.' It outlines the company's rules, principles, approval procedures, risk management, and responsibilities related to external guarantees (i.e., providing guarantees for debts or obligations to third parties). The content is regulatory and governance-related, focusing on internal control, risk management, and compliance with laws and stock exchange rules. There is no indication that this is a financial report, earnings release, or announcement of voting results. It is not a report publication announcement or a certification. The document fits best under Governance Information (CGR) as it details the company's internal rules and governance practices regarding external guarantees.
2025-04-29 Chinese
董事会审计委员会对会计师事务所2024年度履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from the Board Audit Committee regarding the performance and supervision of the external accounting firm for the fiscal year 2024. It discusses the qualifications, risk management, and audit procedures of the accounting firm, as well as the committee's oversight activities and evaluation of the audit work. The content focuses on audit-related information and the committee's supervisory role rather than presenting the full annual financial statements or the company's overall yearly performance. The document is not an Annual Report (10-K) itself but a standalone audit-related report. Therefore, it fits the definition of an Audit Report / Information (AR). The document length is 2718 characters, which is consistent with a detailed report but not a full annual report. Hence, the classification is AR with high confidence.
2025-04-29 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.